Skip to main content
CUPR
NASDAQ Industrial Applications And Services

Cuprina Holdings Receives FDA Clearance for MEDIFLY Maggots, Expanding Wound Care Portfolio

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$5.749
Mkt Cap
$3.655M
52W Low
$1.76
52W High
$76
52W Position info
227% above low
Off High info
92% below high
Rel. Volume info
50× avg
Market data snapshot near publication time

CUPR has more than doubled off its 52-week low of $1.76 on elevated volume (50× avg).

Summary

Cuprina Holdings announced it received U.S. FDA 510(k) clearance for its MEDIFLY Maggots, a medical-grade product for debridement of non-healing wounds, marking a significant regulatory and commercial achievement.


Key Events · Product Development and Regulatory · CUPR

  • FDA 510(k) Clearance Received

    Cuprina Holdings received U.S. FDA 510(k) clearance for MEDIFLY Maggots, its Lucilia cuprina larvae product for debridement of non-healing necrotic skin and soft tissue wounds.

  • First-of-its-Kind Approval

    This is the first U.S. FDA 510(k) clearance for a maggot debridement product using the Lucilia cuprina species, establishing a new market opportunity for the company.

  • Strengthened Market Position

    Cuprina now holds U.S. FDA commercial rights to both Lucilia sericata (licensed) and Lucilia cuprina species for maggot debridement therapy, providing a unique dual-species advantage in the wound care market.

  • International Expansion Potential

    The FDA clearance is expected to support and potentially accelerate regulatory registration pathways for MEDIFLY Maggots in other international markets, including Saudi Arabia, Hong Kong, and mainland China.


Analysis · CUPR · Industrial Applications And Services

This FDA 510(k) clearance for MEDIFLY Maggots is a critical milestone for Cuprina Holdings, a micro-cap biomedical company. It marks the first U.S. clearance for a Lucilia cuprina maggot debridement product, opening the significant U.S. market for chronic wound care. This approval validates the company's product and strengthens its competitive position by giving it commercial rights to both major maggot species used in therapy, which could accelerate international registrations and drive future revenue growth.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CUPR was trading at $5.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $1.76 to $76.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CUPR - Latest Insights

CUPR
Oct 02, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.62
Real-time Price: $1.50 info
Change: -$1.12 (-43%) info
Market Cap: $8.837M info
CUPR
Oct 02, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.62
Real-time Price: $1.50 info
Change: -$1.12 (-43%) info
Market Cap: $8.837M info
CUPR
Sep 29, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.01
Real-time Price: $1.50 info
Change: -$0.510 (-25%) info
Market Cap: $8.837M info
CUPR
Sep 18, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.50 info
Change: -$0.190 (-11%) info
Market Cap: $8.837M info
CUPR
Sep 17, 2026, 9:55 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.50 info
Change: -$0.180 (-11%) info
Market Cap: $8.837M info